No effect of resveratrol supplementation after 6 months on insulin sensitivity in overweight adults: a randomized trial.
glycemic control
insulin resistance
intrahepatic lipid content
obesity
resveratrol
Journal
The American journal of clinical nutrition
ISSN: 1938-3207
Titre abrégé: Am J Clin Nutr
Pays: United States
ID NLM: 0376027
Informations de publication
Date de publication:
01 10 2020
01 10 2020
Historique:
received:
30
01
2020
accepted:
07
05
2020
pubmed:
4
6
2020
medline:
21
11
2020
entrez:
4
6
2020
Statut:
ppublish
Résumé
Effects of resveratrol on metabolic health have been studied in several short-term human clinical trials, with conflicting results. Next to dose, the duration of the clinical trials may explain the lack of effect in some studies, but long-term studies are still limited. The objective of this study was to investigate the effects of 6-mo resveratrol supplementation on metabolic health outcome parameters. Forty-one overweight men and women (BMI: 27-35 kg/m2; aged 40-70 y) completed the study. In this parallel-group, double-blind clinical trial, participants were randomized to receive either 150 mg/d of resveratrol (n = 20) or placebo (n = 21) for 6 mo. The primary outcome of the study was insulin sensitivity, using the Matsuda index. Secondary outcome measures were intrahepatic lipid (IHL) content, body composition, resting energy metabolism, blood pressure, plasma markers, physical performance, quality of life, and quality of sleep. Postintervention differences between the resveratrol and placebo arms were evaluated by ANCOVA adjusting for corresponding preintervention variables. Preintervention, no differences were observed between the 2 treatment arms. Insulin sensitivity was not affected after 6 mo of resveratrol treatment (adjusted mean Matsuda index: 5.18 ± 0.35 in the resveratrol arm compared with 5.50 ± 0.34 in the placebo arm), although there was a significant difference in postintervention glycated hemoglobin (HbA1c) between the arms (P = 0.007). The adjusted means showed that postintervention HbA1c was lower on resveratrol (35.8 ± 0.43 mmol/mol) compared with placebo (37.6 ± 0.44 mmol/mol). No postintervention differences were found in IHL, body composition, blood pressure, energy metabolism, physical performance, or quality of life and sleep between treatment arms. After 6 mo of resveratrol supplementation, insulin sensitivity was unaffected in the resveratrol arm compared with the placebo arm. Nonetheless, HbA1c was lower in overweight men and women in the resveratrol arm. This trial was registered at Clinicaltrials.gov as NCT02565979.
Sections du résumé
BACKGROUND
Effects of resveratrol on metabolic health have been studied in several short-term human clinical trials, with conflicting results. Next to dose, the duration of the clinical trials may explain the lack of effect in some studies, but long-term studies are still limited.
OBJECTIVES
The objective of this study was to investigate the effects of 6-mo resveratrol supplementation on metabolic health outcome parameters.
METHODS
Forty-one overweight men and women (BMI: 27-35 kg/m2; aged 40-70 y) completed the study. In this parallel-group, double-blind clinical trial, participants were randomized to receive either 150 mg/d of resveratrol (n = 20) or placebo (n = 21) for 6 mo. The primary outcome of the study was insulin sensitivity, using the Matsuda index. Secondary outcome measures were intrahepatic lipid (IHL) content, body composition, resting energy metabolism, blood pressure, plasma markers, physical performance, quality of life, and quality of sleep. Postintervention differences between the resveratrol and placebo arms were evaluated by ANCOVA adjusting for corresponding preintervention variables.
RESULTS
Preintervention, no differences were observed between the 2 treatment arms. Insulin sensitivity was not affected after 6 mo of resveratrol treatment (adjusted mean Matsuda index: 5.18 ± 0.35 in the resveratrol arm compared with 5.50 ± 0.34 in the placebo arm), although there was a significant difference in postintervention glycated hemoglobin (HbA1c) between the arms (P = 0.007). The adjusted means showed that postintervention HbA1c was lower on resveratrol (35.8 ± 0.43 mmol/mol) compared with placebo (37.6 ± 0.44 mmol/mol). No postintervention differences were found in IHL, body composition, blood pressure, energy metabolism, physical performance, or quality of life and sleep between treatment arms.
CONCLUSIONS
After 6 mo of resveratrol supplementation, insulin sensitivity was unaffected in the resveratrol arm compared with the placebo arm. Nonetheless, HbA1c was lower in overweight men and women in the resveratrol arm. This trial was registered at Clinicaltrials.gov as NCT02565979.
Identifiants
pubmed: 32492138
pii: S0002-9165(22)00867-X
doi: 10.1093/ajcn/nqaa125
pmc: PMC7528554
doi:
Substances chimiques
Glycated Hemoglobin A
0
hemoglobin A1c protein, human
0
Resveratrol
Q369O8926L
Banques de données
ClinicalTrials.gov
['NCT02565979']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1029-1038Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © The Author(s) on behalf of the American Society for Nutrition 2020.
Références
Arterioscler Thromb Vasc Biol. 2013 Dec;33(12):2895-901
pubmed: 24072699
Am J Lifestyle Med. 2013 Nov-Dec;7(6):395-404
pubmed: 27547170
J Clin Endocrinol Metab. 2017 May 1;102(5):1642-1651
pubmed: 28182820
Biol Chem. 2010 Sep;391(9):1057-65
pubmed: 20536388
Am J Clin Nutr. 2016 Jul;104(1):215-27
pubmed: 27194304
Clin Geriatr Med. 2009 Nov;25(4):733-43, ix-x
pubmed: 19944270
Nutr Rev. 2013 Dec;71(12):822-35
pubmed: 24111838
Am J Clin Nutr. 2015 Jan;101(1):65-71
pubmed: 25527751
Diabetes Res Clin Pract. 2011 Sep;93(3):312-3
pubmed: 21820751
Cell Metab. 2011 Nov 2;14(5):612-22
pubmed: 22055504
Pharmacol Res. 2018 Mar;129:141-150
pubmed: 29305228
PLoS One. 2015 Mar 19;10(3):e0118393
pubmed: 25790328
Nutrients. 2016 Jan 29;8(2):73
pubmed: 26840331
J Gerontol A Biol Sci Med Sci. 2017 Nov 9;72(12):1595-1606
pubmed: 28505227
Can J Sport Sci. 1991 Mar;16(1):23-9
pubmed: 1645211
Diabetologia. 2011 May;54(5):1147-56
pubmed: 21327867
Radiology. 2009 Jan;250(1):95-102
pubmed: 19092092
Dig Liver Dis. 2015 Mar;47(3):226-32
pubmed: 25577300
Nature. 2003 Sep 11;425(6954):191-6
pubmed: 12939617
Psychiatry Res. 1989 May;28(2):193-213
pubmed: 2748771
Biochim Biophys Acta. 2015 Jun;1852(6):1137-44
pubmed: 25446988
Cell. 2006 Dec 15;127(6):1109-22
pubmed: 17112576
Biol Chem. 2014 Mar;395(3):347-54
pubmed: 24150206
Ann N Y Acad Sci. 2009 Sep;1173 Suppl 1:E10-9
pubmed: 19751409
Diabetes Care. 2009 Nov;32 Suppl 2:S157-63
pubmed: 19875544
J Gerontol A Biol Sci Med Sci. 2012 Dec;67(12):1307-12
pubmed: 22219517
J Physiol. 2014 Apr 15;592(8):1873-86
pubmed: 24514907
Diabetes Obes Metab. 2018 Jul;20(7):1793-1797
pubmed: 29484808
Diabetes. 2013 Apr;62(4):1186-95
pubmed: 23193181
J Physiol. 1949 Aug;109(1-2):1-9
pubmed: 15394301
J Neurosci. 2014 Jun 4;34(23):7862-70
pubmed: 24899709
JAMA Cardiol. 2017 Aug 1;2(8):902-907
pubmed: 28403379
Am J Clin Nutr. 2014 Jun;99(6):1510-9
pubmed: 24695890
Diabetes Care. 1999 Sep;22(9):1462-70
pubmed: 10480510
Br J Nutr. 2011 Aug;106(3):383-9
pubmed: 21385509
Nutr Res. 2012 Jul;32(7):537-41
pubmed: 22901562
Diabetes Care. 2016 Dec;39(12):2211-2217
pubmed: 27852684
Evid Based Complement Alternat Med. 2013;2013:851267
pubmed: 24073011
Metab Syndr Relat Disord. 2014 Dec;12(10):497-501
pubmed: 25137036
Clin Gastroenterol Hepatol. 2014 Dec;12(12):2092-103.e1-6
pubmed: 24582567
Cell Metab. 2012 Nov 7;16(5):658-64
pubmed: 23102619
Am J Clin Nutr. 1982 Nov;36(5):936-42
pubmed: 7137077
BMC Physiol. 2010 Jun 22;10:11
pubmed: 20569453
Am J Physiol Endocrinol Metab. 2018 Feb 1;314(2):E165-E173
pubmed: 29118014
Age (Dordr). 2011 Mar;33(1):15-31
pubmed: 20532988
PLoS One. 2013;8(3):e57622
pubmed: 23516412
Mol Metab. 2018 Jun;12:39-47
pubmed: 29706321